<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939835</url>
  </required_header>
  <id_info>
    <org_study_id>US/05/002</org_study_id>
    <nct_id>NCT00939835</nct_id>
  </id_info>
  <brief_title>Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition</brief_title>
  <official_title>A Randomized, Single Dose, Open Label, Bioequivalence Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      -  Objective:&#xD;
&#xD;
             -  The objective of this study is to compare the rate and extent of absorption of the&#xD;
                Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Limited) to the&#xD;
                Reference Product, RLD Tablets 40 mg (Forest Pharmaceuticals Inc, Missouri) under&#xD;
                fed condition&#xD;
&#xD;
        -  Study Design:&#xD;
&#xD;
             -  Randomized, Single Dose, Open Label, Non-Replicate, Two-period, Two-treatment, Two-&#xD;
                Sequence Crossover Bioequivalence Study comparing Citalopram Hydrobromide Tablets&#xD;
                40 mg (manufactured by Torrent Pharmaceuticals Ltd). With RLD Tablets 40 mg&#xD;
                (manufactured by Forest Pharmaceuticals Inc Missouri) in 24+2 normal healthy male&#xD;
                subjects with a wash out period of 15 days between the two study periods, in fed&#xD;
                condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram Hydrobromide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects in the range of 18 - 45 years of age.&#xD;
&#xD;
          -  Body weight within Â± 15% of the weight range as related to height, as per the Life&#xD;
             Insurance Corporation (LIC) Chart. (Appendix A)&#xD;
&#xD;
          -  No abnormal findings as determined by baseline history, physical examination, vital&#xD;
             signs (blood pressure, pulse rate, respiration rate and body temperature)&#xD;
             hematological tests, serum chemistry, urinalysis, ECG and Chest X-ray.&#xD;
&#xD;
          -  Subjects having values above/below the reference range, (Appendix J) for&#xD;
             hematological, serum chemistry and urine analysis values will be clinically correlated&#xD;
             for signs and symptoms. These subjects will be included if found asymptomatic.&#xD;
&#xD;
          -  Willingness to follow, the protocol requirements, as evidenced by written, informed&#xD;
             consent.&#xD;
&#xD;
          -  Agreeing to, not to use any medication (prescription and over the counter), including&#xD;
             vitamins and minerals for 15 days prior to study &amp; during the course of the study.&#xD;
&#xD;
          -  No history or presence of significant alcoholism or drug abuse in the past one year.&#xD;
&#xD;
          -  Subjects should preferably be non-smokers. If moderate smokers are included (less than&#xD;
             10 cigarette per day) as per guidelines will be identified as such and documented in&#xD;
             the history taking form in CRF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requiring medication for any ailment.&#xD;
&#xD;
          -  Any medical or surgical conditions, which might significantly interfere with the&#xD;
             functioning of gastrointestinal tract, blood-forming organs etc.&#xD;
&#xD;
          -  History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,&#xD;
             metabolic or psychiatric diseases.&#xD;
&#xD;
          -  Participation in a clinical drug study or Bioequivalence study 90 days prior to&#xD;
             present study.&#xD;
&#xD;
          -  History of malignancy or other serious diseases.&#xD;
&#xD;
          -  Refusal to abstain from food for ten (10) hours prior to study drug administration on&#xD;
             first day of each study period and for four (4) additional hours each, post dose.&#xD;
&#xD;
          -  Refusal to abstain from water for one (1) hour prior to study drug administration on&#xD;
             first day of each study period and for one (1) additional hour, post dosing.&#xD;
&#xD;
          -  Any contraindication to blood sampling.&#xD;
&#xD;
          -  Smoking or consumption of tobacco products during the study.&#xD;
&#xD;
          -  Use of xanthine-containing beverages or food for 48 hours prior to each drug dose.&#xD;
&#xD;
          -  Blood donation 30 days prior to the commencement of the study.&#xD;
&#xD;
          -  Subjects with positive HIV tests.&#xD;
&#xD;
          -  Subjects with positive HbsAg or Hepatitis-C tests.&#xD;
&#xD;
          -  Known history of hypersensitivity Citalopram or related drugs.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  At the time of screening, prior to enrollment, presence of pregnancy will be confirmed&#xD;
             by urine pregnancy test.&#xD;
&#xD;
          -  Just prior to commencement of study (for both periods), presence of pregnancy will be&#xD;
             confirmed by urine pregnancy test.&#xD;
&#xD;
          -  Female subjects not confirm to using birth control measures, from the date of&#xD;
             screening till the completion of the second period of the study. Abstinence, barrier&#xD;
             methods (condom, diaphragm, etc.) are acceptable. Use of hormonal contraceptives&#xD;
             either oral or implants will not be acceptable.&#xD;
&#xD;
          -  Female subjects whose menstruation cycle coincides with the study periods.&#xD;
&#xD;
          -  History of drug abuse in the past one year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Accutest Research Laboratories Pvt. Ltd.</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 709</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

